Abrasive tool making process – material – or composition – With carbohydrate or reaction product thereof
Reexamination Certificate
2007-02-13
2007-02-13
Witz, Jean C. (Department: 1651)
Abrasive tool making process, material, or composition
With carbohydrate or reaction product thereof
C514S021800
Reexamination Certificate
active
10029206
ABSTRACT:
The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of anthrax. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof.
REFERENCES:
patent: 4977244 (1990-12-01), Muchmore et al.
patent: 5380668 (1995-01-01), Herron
patent: 5677275 (1997-10-01), Lunardi-Iskandar et al.
patent: 5851997 (1998-12-01), Harris
patent: 5854004 (1998-12-01), Czernilofsky et al.
patent: 5877148 (1999-03-01), Lunardi-Iskandar et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5968513 (1999-10-01), Gallo et al.
patent: 5997871 (1999-12-01), Gallo et al.
patent: 6150500 (2000-11-01), Salerno
patent: 6319504 (2001-11-01), Gallo et al.
patent: 6361992 (2002-03-01), Szkudlinski et al.
patent: 6489296 (2002-12-01), Grinnell et al.
patent: 6583109 (2003-06-01), Gallo et al.
patent: 6596688 (2003-07-01), Gallo et al.
patent: 6620416 (2003-09-01), Gallo et al.
patent: 6727227 (2004-04-01), Khavinson
patent: 6844315 (2005-01-01), Khan et al.
patent: 2002/0041871 (2002-04-01), Brudnak
patent: 2002/0064501 (2002-05-01), Khan et al.
patent: 2003/0049273 (2003-03-01), Gallo et al.
patent: 2003/0113733 (2003-06-01), Khan et al.
patent: 2003/0119720 (2003-06-01), Khan et al.
patent: 2003/0166556 (2003-09-01), Khan et al.
patent: 2003/0186244 (2003-10-01), Margus et al.
patent: 2003/0215434 (2003-11-01), Khan et al.
patent: 2003/0219425 (2003-11-01), Khan et al.
patent: 2003/0220257 (2003-11-01), Benner et al.
patent: 2003/0220258 (2003-11-01), Benner et al.
patent: 2003/0220259 (2003-11-01), Benner et al.
patent: 2003/0220260 (2003-11-01), Khan et al.
patent: 2003/0220261 (2003-11-01), Khan et al.
patent: 2003/0224995 (2003-12-01), Khan et al.
patent: 2004/0013661 (2004-01-01), Wensvoort et al.
patent: 3715662 (1987-11-01), None
patent: 19953339 (2001-05-01), None
patent: 1 138 692 (2001-10-01), None
patent: 1 300 418 (2003-04-01), None
patent: 2 706 772 (1994-12-01), None
patent: 96/04008 (1996-02-01), None
patent: 97/49373 (1997-12-01), None
patent: 97/49418 (1997-12-01), None
patent: 97/49432 (1997-12-01), None
patent: WO 97/49721 (1997-12-01), None
patent: WO 98/35691 (1998-08-01), None
patent: WO 99/59617 (1999-11-01), None
patent: WO 01/10907 (2001-02-01), None
patent: WO 01/11048 (2001-02-01), None
patent: WO 01/29067 (2001-04-01), None
patent: WO 01/72831 (2001-10-01), None
patent: WO 02/085117 (2002-10-01), None
patent: WO 03/029292 (2003-04-01), None
Cui et al., Am. J. Physiol. Integr. Comp. Physiol. 286: R699-R709 (2004).
Moayeri et al., Journal of Clinical Investigation 112(5): 670-682 (Sep. 2003).
Kalns et al., Biochem. Biophys. Res. Comm. 297: 506-509 (2002).
Kalns et al., Biochem. Biophys. Res. Comm. 292: 41-44 (2002).
Pellizzari et al., FEBS Letters 462: 199-204 (1999).
PCT International Search Report, PCT/NL01/00259, dated Dec. 18, 2001, 3 pages.
PCT International Preliminary Examination Report, PCT/NL99/00313, dated Jul. 21, 2000, 6 pages.
PCT International Search Report, PCT/EP99/00313, dated Nov. 29, 1999, 3 pages.
Lang et al., “Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin”,AIDS1997, vol. 11, No. 11, pp. 1333-1340.
Iskandar et al., “Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease”,Nature Medicine, Apr. 1998, vol. 4, No. 4, pp. 428-434.
#International Search Report, International Application No. PCT/NL02/00639, mailed Aug. 4, 2003 (8 pages).
#Christman et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy, Intens Care Med, 1998, pp. 1131-1138, vol. 24.
#Jyonouchi et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-179, vol. 120.
#Kanungo et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, vol. 20.
#Rohrig et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, vol. 289.
#Tak et al., NF-kappaB: a key role in inflammatory diseases, J Clin Invest., 2001, pp. 7-11, vol. 107.
#Tan et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, vol. 55.
#Tovey et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-921, vol. 19.
#Albini, A., et al., “Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin,” 17 Clinical & Experimental Metastasis 739 (1999).
#Blackwell, Timothy S., et al., “The Role of Nuclear Factor-kB in Cytokine Gene Regulation,” 17 Am. J. Respir. Cell Mol. Biol. 3-9 (1997).
#Keller, S., et al., “Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cellsin Vitro,” 20(5-6) PLACENTA, p. A37 (Jul. 1999).
#Khan, Nisar A., et al., “Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor,” 62(12) Human Immunology 1315-1323 (Dec. 2001).
#Khan, Nisar A., et al., “Inhibition of Septic Shock in Mice by an Oligopeptide From the β-Chain of Human Chorionic Gonadotrophin Hormone,” 63(1) Human Immunology 1-7 (Jan. 2002).
#Muchmore et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, Mar. 1997, pp. 881-886, vol. 118, No. 3.
#Muchmore et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, Dec. 1984, pp. 1672-1685, vol. 160.
#Patil, A., et al., “The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study,” 87 ACTA Neurochir (WIEN) 76-78 (1987).
#Slater, Lewis M., et al., “Decreased Mortality of Murine Graft-Versus-Host Disease by Human Chorionic gonadotropin,” 23(1) Transplantation 103-104 (Jan. 1977).
#Wulczyn, F. Gregory, et al., “The NF-kB/Rel and IkB gene families: mediators of immune response and inflammation,” 74(12) J. Mol. Med. 749-769 (1996).
#Yamamoto, Y., et al., “Role of the NF-kB Pathway in the Pathogenesis of Human Disease States,” 1(3) Current Molecular Medicine 287-296 (Jul. 2001).
Connelly et al., Biphasic Regulation of NF-kB Activity Underties the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-3881, 166, The American Association of Immunologists, USA.
Friedlander, Tackling anthrax, Nature, Nov. 8, 2001, pp. 160-161, vol. 414.
Medzhitov, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, Nov. 2001, pp. 135-145, vol. 1.
Kachra et al., “Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells,” Endocrinology, 1997, pp. 4038-4041, vol. 138, No. 9.
Khavinson et al., “Mechanisms Underlying Geroprotective Effects of Peptides,” Bulletin of Experimental Biology and Medicine, Jan. 2002, pp. 1-5, vol. 133, No. 1.
Khavinson et al., “Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell,” Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, vol. 137, No. 5.
Morozov et al., “Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction,” Int. J. Immunopharmac., 1997, pp. 501-505, vol. 19, No. 9/10.
Khavinson et al., “Inductive Activity of Retinal Peptides,” Bulletin of Experimental Biology and M
Benner Robert
Khan Nisar Asmed
Biotempt B.V.
TraskBritt
Witz Jean C.
LandOfFree
Oligopeptide treatment of NF-κB mediated inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligopeptide treatment of NF-κB mediated inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligopeptide treatment of NF-κB mediated inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834399